Virta Intervention in CommuniTies in COloRado (VICTOR-Pilot) Pilot Study to Improve Diabetes and Cardiovascular Risk in Rural Communities
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 6
- 主要终点
- Change in hemoglobin A1c (Percent)
研究概览
简要总结
The VICTOR study plans to include rural communities served by Colorado Heart Healthy Solutions (CHHS) program and find out whether participants will accept a referral to a comprehensive virtual lifestyle intervention, Virta Health. The Virta Health program induces nutritional ketosis to improve glucose control in individuals with type 2 diabetes. The study will inform the acceptability of the referral, the retention of participants in lifestyle intervention, and the durability of effects on glucose control after the lifestyle intervention has ended.
详细描述
In rural communities served by Colorado Heart Healthy Solutions (CHHS), referral to a comprehensive remotely-delivered (virtual) continuous remote care to induce nutritional ketosis combined with remote medication management will improve glycemic control in patients with type 2 diabetes as compared with standard care. The study intervention is the referral. Subjects are not mandated to receive Virta treatment and are welcome to continue in the study whether or not the referral is accepted. 2 rural communities served by CHHS have been chosen as recruitment sites. Study patients will be randomized at the site level.
Objectives
Primary: To assess glycemic control in patients with type 2 diabetes living in a rural community referred to a comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management (termed "continuous remote care") as compared with those living in a rural community offered standard care.
Secondary:
- To assess the effects of referral to continuous remote care as compared with standard care on body weight and on body mass index
- To assess the effects of referral to continuous remote care as compared with standard care on number and doses of anti-hyperglycemic medications
- To determine the durability of a continuous remote care intervention when paired with ongoing community health worker support
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to provide electronic informed consent
- •Age 18 - 79 years old
- •Type 2 diabetes mellitus diagnosis by self-report and/or medical history
- •Taking 1 or more antihyperglycemic medications
- •Current HbA1c > 7.5%
- •Body mass index (BMI) 25 kg/m2 or greater
- •Capable of engaging in virtual care
排除标准
- •Type 1 diabetes
- •Pregnant or planning pregnancy within the next 9 months
- •Admission for diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) within the last 12 months
- •Life expectancy <1 year
- •Postural orthostatic tachycardia syndrome (POTS) and/or recurrent syncope
- •Active severe psychiatric or medical condition(s) such as advanced renal (end-stage renal disease or CKD stage 4 or 5; eGFR <30 mL/min), cardiac (NYHA Class 4 heart failure), or hepatic dysfunction (Child-Pugh Class C)
- •Any condition which in the opinion of the investigator would make the study unsuitable for the subject including investigator opinion regarding inability to comply with Virta instructions
结局指标
主要结局
Change in hemoglobin A1c (Percent)
时间窗: 3.5 months
Change from baseline hemoglobin A1c (Percent) among patients referred to continuous remote care (Group 1) versus standard care (Group 2)
次要结局
- Change in BMI(Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus10 months)
- Change in hemoglobin A1c(3.5 months versus 7 months, baseline versus 10 months)
- Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications(Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus 10 months)